Antibe Reports Q2 2024 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.
- Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.
- While trial initiation remains set for calendar Q1 2024, the Company now anticipates top-line results in calendar Q3 2024.
- General and Administrative Expenses: General and administrative expenses were $1.9 million, compared to $1.7 million in fiscal Q2 2023.
- The Company’s unaudited fiscal Q2 2024 condensed interim financial statements and MD&A are available on SEDAR.